NASDAQ:CELU Celularity Q1 2026 Earnings Results & Report $0.98 -0.07 (-6.89%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.97 -0.01 (-0.79%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Celularity reported Q1 2026 earnings on October 20, 2026. The company reported EPS of $0.02, while revenue was $5.43 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateOctober 20, 2026TimeAfter Market Closes Celularity EPS ResultsActual EPS$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate6 of last 6 quartersCelularity Revenue ResultsActual Revenue$5.43 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCelularity's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Celularity Q1 2026 Earnings FAQ Did Celularity beat earnings estimates for Q1 2026? Celularity (NASDAQ:CELU) reported earnings of $0.02 per share for Q1 2026. The report was announced on Tuesday, October 20, 2026. What was Celularity's revenue for Q1 2026? Celularity reported revenue of $5.43 million for Q1 2026. When is Celularity's next earnings date? Celularity's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Celularity on the company's earnings history page. Celularity Earnings HeadlinesCelularity Regains Compliance with Nasdaq Periodic Reporting RequirementOctober 22 at 8:00 AM | globenewswire.comCelularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026October 21, 2026 | marketscreener.comMEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.October 25 at 1:00 AM | Behind the Markets (Ad)Viome CEO Jain to join board of directors at Florham Park-based CelularityOctober 1, 2026 | roi-nj.comRCelularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic PartnerSeptember 30, 2026 | globenewswire.comCelularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026September 29, 2026 | marketscreener.comMSee More Celularity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email. Email Address About CelularityCelularity (NASDAQ:CELU) (NASDAQ: CELU) is a biotechnology company developing and commercializing therapies and biomaterial products derived from human placental tissue. Its work focuses on regenerative medicine and cellular therapy, including allogeneic, or donor-derived, cell products intended for applications in oncology, immune-mediated diseases, and tissue repair. The company’s research pipeline has included placenta-derived natural killer (NK) cell therapies, such as CYNK-001, an investigational product studied for certain blood cancers, and other cell-based programs designed to address cancer and inflammatory conditions. Celularity has also developed placental-derived biomaterials for wound care and surgical applications, including products based on amniotic membrane and placental connective tissue matrices. Founded in 2016 by biotechnology and medical entrepreneur Robert J. Hariri, Celularity is headquartered in Florham Park, New Jersey. The company became a publicly traded business in 2021 through a merger with a special purpose acquisition company. Its products and development programs are intended for use in the United States and potentially other markets, subject to regulatory approvals and commercial availability.View Celularity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineNewmont’s Record Quarter Shows Why Gold’s Floor Is the Real StoryLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
